Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03511690 · ClinicalTrials.gov registry record · NA
Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment
A NA study of Hereditary Breast and Ovarian Cancer, sponsored by Georgetown University.
- Completed
- Registry status
- NA
- Development phase
- 95
- Enrollment target
- 4
- Study locations
NCT03511690: Completed NA study of Hereditary Breast and Ovarian Cancer, sponsored by Georgetown University.
NCT03511690 is a NA study of Hereditary Breast and Ovarian Cancer that has completed, run by Georgetown University. The registered enrollment target is 95 participants, below the 587-participant average among 5 other Hereditary Breast and Ovarian Cancer trials with a reported enrollment target (84% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03511690, a NA study of Hereditary Breast and Ovarian Cancer, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- NA
- Development phase
- 95 participants
- Enrollment target
- 4
- Study locations
Study Summary
Participating in genetic cancer risk assessments (GCRA) for hereditary breast and ovarian cancer can inform treatment and risk management decisions and improve breast cancer outcomes. However, Latina and Black women underuse GCRA services, which may increase breast cancer disparities. This study will adapt and test the impact of an easily scalable novel Tutoring System intervention to enhance GCRA use and improve psychosocial outcomes in a clinical sample of underserved Latina and Black women at risk of hereditary breast and ovarian cancer.
Primary Outcome
Breast cancer genetics knowledge will be assessed with 13-items from Erblich and colleagues' scale where participants evaluate whether statements about breast cancer genetics are true or false. The numbers of correct responses are added to create a score ranging from 0-13. Higher scores mean higher breast cancer genetics knowledge.
Conditions Studied
Interventions
- BEHAVIORAL BRCA-Gist
Study Locations (4)
District of Columbia
- Capital Breast Care Center - Washington D.C.
- Georgetown University - Washington D.C.
Virginia
- Nueva Vida - Alexandria
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2022-02-20 |
| Phase | NA |
What the finished NCT03511690 record still lists
NCT03511690 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, below the 587-participant average among 5 other Hereditary Breast and Ovarian Cancer trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Hereditary Breast and Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which BRCA-Gist is the first listed.
NCT03511690 reports a single indexed study location in District of Columbia, Virginia.
Frequently Asked Questions
What is clinical trial NCT03511690 about?
NCT03511690 is a clinical study titled "Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment". Participating in genetic cancer risk assessments (GCRA) for hereditary breast and ovarian cancer can inform treatment and risk management decisions and improve breast cancer outcomes. However, Latina and Black women underuse GCRA services, which may increase breast cancer disparities. This study wil...
What is the current status of trial NCT03511690?
This trial is currently completed. It is a NA study. The enrollment target is 95 participants. The study started on 2017-07-01. Estimated completion is 2022-02-20.
What conditions does trial NCT03511690 study?
This clinical trial studies the following conditions: Hereditary Breast and Ovarian Cancer.
What interventions are being tested in trial NCT03511690?
The interventions under investigation include: BRCA-Gist (BEHAVIORAL).
Who is sponsoring clinical trial NCT03511690?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03511690 being conducted?
This trial has 4 study locations across District of Columbia, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Breast and Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
RECRUITING · NA
-
Scalable Communication Modalities for Returning Genetic Research Results
ACTIVE NOT RECRUITING · NA
-
Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer
COMPLETED · NA
-
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
RECRUITING
-
Genetic Risk: Whether, When, and How to Tell Adolescents
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI